Can you provide the average price target for MDXHEALTH stock?
12 analysts have analysed MDXH and the average price target is 7.55 USD. This implies a price increase of 270% is expected in the next year compared to the current price of 2.04.
MDXHEALTH (MDXH) Forecast, Price Target & Analyst Ratings
NASDAQ:MDXH • BE0974461940
Current stock price
2.04 USD
-0.03 (-1.45%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MDXHEALTH (MDXH).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 14, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.16
- Revenue Estimate
- 31.232M
Price Target Details & History
Consensus Price Target and Range
Mean target
$7.55
Upside
+ 270.00%
From current price of $2.04 to mean target of $7.55, Based on 12 analyst forecasts
Low
$6.06
Median
$7.14
High
$9.45
Price Target Revisions
1 Month
0.00%
3 Months
5.11%
Price Target Summary
12 Wall Street analysts provided a forecast for the next 12 months for MDXH. The average price target is 7.55 USD. This implies a price increase of 270% is expected in the next year compared to the current price of 2.04.
The average price target has been revised upward by 5.11% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
86.67%
MDXH was analyzed by 12 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about MDXH.
In the previous month the buy percentage consensus was at a similar level.
MDXH was analyzed by 12 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-12-23 | BTIG | Reiterate | Buy -> Buy |
| 2025-11-13 | TD Cowen | Maintains | Buy -> Buy |
| 2025-11-13 | Lake Street | Maintains | Buy -> Buy |
| 2025-11-13 | BTIG | Maintains | Buy -> Buy |
| 2024-11-07 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-10-31 | Lake Street | Initiate | Buy |
| 2024-03-07 | BTIG | Maintains | Buy -> Buy |
| 2024-03-07 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-11-09 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-05-31 | TD Cowen | Initiate | Outperform |
| 2023-05-16 | BTIG | Maintains | Buy -> Buy |
| 2023-03-24 | William Blair | Initiate | Outperform |
| 2023-03-06 | Piper Sandler | Maintains | Overweight |
| 2022-08-26 | BTIG | Maintains | Buy |
| 2021-11-29 | BTIG | Initiate | Buy |
| 2021-11-29 | Oppenheimer | Initiate | Outperform |
| 2021-11-29 | Piper Sandler | Initiate | Overweight |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 14, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.16
- Revenue Estimate
- 31.232M
- Revenue Q2Q
- 28.57%
- EPS Q2Q
- 18.40%
- Number of Analysts
- 7
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
-3.33%
EPS (1 Month)
-2.70%
EPS (3 Months)
-55.90%
Next Earnings Summary
MDXH is expected to report earnings on 5/14/2026. The consensus EPS estimate for the next earnings is -0.16 USD and the consensus revenue estimate is 31.23M USD.
The next earnings revenue estimate has been revised downward by 3.33% in the past 3 months.
Full Analyst Estimates 2026 - 2029
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 70.193M 89.45% | 90.049M 28.29% | 107.875M 19.80% | 141.08M 30.78% | 166.91M 18.31% | 198.49M 18.92% | 236.86M 19.33% | |
| EBITDA YoY % growth | -20.468M 37.88% | -16.683M 18.49% | -5.2M 68.83% | 4.549M 187.48% | 20.788M 356.98% | 30.804M 48.18% | 36.635M 18.93% | |
| EBIT YoY % growth | -27.327M 27.82% | -24.722M 9.53% | -14.408M 41.72% | -4.552M 68.40% | 9.334M 305.03% | 18.768M 101.07% | 36.635M 95.20% | |
| Operating Margin | -38.93% | -27.45% | -13.36% | -3.23% | 5.59% | 9.46% | 15.47% | |
| EPS YoY % growth | -1.59 43.21% | -1.27 20.13% | -0.67 47.24% | -0.43 35.55% | -0.16 63.15% | 0.07 144.87% | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.16 18.40% | -0.12 18.40% | -0.10 36.25% | -0.08 54.40% | -0.11 30.92% | -0.04 66.67% | -0.03 75.00% | -0.01 86.84% |
| Revenue Q2Q % growth | 31.232M 28.57% | 34.374M 29.20% | 36.475M 32.96% | 38.658M 30.84% | 36.958M 18.33% | 40.902M 18.99% | 43.078M 18.10% | 45.22M 16.97% |
| EBITDA Q2Q % growth | -1.224M 47.71% | 586.5K 129.46% | 1.964M -52.39% | 3.57M 173.77% | 2.55M 308.33% | 5.202M 786.96% | 7.344M 273.93% | 8.466M 137.14% |
| EBIT Q2Q % growth | -4.463M 2.74% | -2.754M 57.66% | -1.377M 47.88% | 127.5K 101.61% | -2.04M 54.29% | 867K 131.48% | 1.989M 244.44% | 2.04M 1,500.00% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
28.19%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
21.35%
Revenue Next 5 Year
20.84%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
70.74%
EBIT Next 5 Year
53.43%
MDXHEALTH / MDXH Forecast FAQ
When does MDXHEALTH (MDXH) report earnings?
MDXHEALTH (MDXH) will report earnings on 2026-05-14.
What are the consensus estimates for MDXH stock next earnings?
The consensus EPS estimate for the next earnings of MDXHEALTH (MDXH) is -0.16 USD and the consensus revenue estimate is 31.23M USD.
What is the consensus rating for MDXHEALTH (MDXH) stock?
The consensus rating for MDXHEALTH (MDXH) is 86.6667 / 100 . This indicates that analysts generally have a positive outlook on the stock.